The precipitous market decline saw EyePoint stock drop $9.88 per share, closing at $4.87 following the release of the LUGANO trial data. The disappointing results for the vorolanib intravitreal insert have now prompted Pomerantz LLP to open a formal investigation into potential securities fraud. The legal firm is scrutinizing whether EyePoint executives or directors misled shareholders regarding the company's business practices or the developmental progress of its lead therapeutic candidate. Investors seeking to participate in the potential class action are being directed to contact Danielle Peyton at Pomerantz LLP to discuss their legal standing and the specifics of the ongoing probe.
Pomerantz LLP Launches Investigation Into EyePoint Following Clinical Trial Miss
Shares of EyePoint Pharmaceuticals plummeted 67% on August 17 after the company reported that its pivotal Phase 3 trial for the wet age-related macular degeneration treatment DURAVYU failed to meet key visual acuity benchmarks when measured against the industry-standard drug Eylea.
Comments (0)
No comments yet. Be the first!